LOX and cancer: The use ofcombination of LOX and COX specific inhibitors has been described in colon andpancreatic cancer models [47, 48].Recently, Schroeder et al. [49]have reported that treatment of A549 lung cancer cell line and transformed cell1198, derived from BEAS-2B, with a triple combination of clinical relevant concentrationsof celecoxib (COX inhibitor), MK886, and REV 5901 (both LOX inhibitors)resulted in significant suppression of growth and cell death induction in bothcell lines.